These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 28152315

  • 1. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
    Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EAF, Scientific Committee for Elucidation of Infantile Asthma.
    Am J Respir Crit Care Med; 2017 Jul 01; 196(1):29-38. PubMed ID: 28152315
    [Abstract] [Full Text] [Related]

  • 2. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
    Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA, C-CREW Investigators.
    Pediatrics; 2013 Nov 01; 132(5):811-8. PubMed ID: 24127479
    [Abstract] [Full Text] [Related]

  • 3. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
    Kato M, Mochizuki H, Kama Y, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EAF, Scientific Committee for Elucidation of Infantile Asthma (SCELIA).
    Pediatr Pulmonol; 2024 Mar 01; 59(3):743-749. PubMed ID: 38116923
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL, Palivizumab Long-Term Respiratory Outcomes Study Group.
    J Pediatr; 2007 Jul 01; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [Abstract] [Full Text] [Related]

  • 5. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
    Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR, Palivizumab Long-Term Respiratory Outcomes Study Group.
    J Allergy Clin Immunol; 2010 Aug 01; 126(2):256-62. PubMed ID: 20624638
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.
    BMC Infect Dis; 2017 Oct 17; 17(1):687. PubMed ID: 29041909
    [Abstract] [Full Text] [Related]

  • 8. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH, Scheltema NM, Clerc M, van Houten MA, Nibbelke EE, Achten NB, Arp K, Sanders EAM, Bont LJ, Bogaert D.
    Lancet Respir Med; 2020 Oct 17; 8(10):1022-1031. PubMed ID: 32203712
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V, Scarcella A, Puddu M, Gallini F, Tuminelli F, Bragetti P, Gallina MR, Quartulli L, Benincori N, Citro G, Via LD, Barera G, DI Luzio Paparatti U, Merolla R, Romano GV, Guida G, Silvestri M, Rossi GA.
    J Chemother; 2009 Jun 17; 21(3):302-10. PubMed ID: 19567351
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE, Huertas VM.
    BMC Infect Dis; 2024 Apr 19; 24(1):418. PubMed ID: 38641577
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun 19; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.